13554 Background: S, an oral platinum (P) compound, has single agent anti-tumor activity. C, an oral pro-drug of 5-FU, has efficacy against many solid tumors. Furthermore, P agents and 5-FU have synergistic activity in a variety of tumor types. Methods: The primary objective was to determine the maximally tolerated dose (MTD) of concurrent S and C. Secondary objectives were to evaluate the safety and efficacy of S and C. C was dosed at 825mg/m2 bid on days 1–14 of each 21 day cycle. S was given qd on days 1–5 starting at 60mg/m2 for the first cohort. If dose limiting toxicity (DLT) was not observed, the S dose was escalated by increments of 20mg/m2 for subsequent cohorts. Cycle 1 DLT was defined as ≥ grade (gr) 3 neutropenia or thrombocytopenia lasting for ≥5 days or gr 4 neutropenia with fever. Persistent gr 2 neuropathy or ≥gr 3 non- hematologic toxicities including neuropathy, gastrointestinal or renal toxicity were also DLTs. Eligible pts had treatment refractory metastatic/unresectable solid tumors, ...